Loading…
Kiora Pharmaceuticals Inc Is A Clinical-Stage Biotechnology Company Developing And Commercializing Products For The Treatment Of Orphan Retinal Diseases. As Part Of Its Development, Kio-301 Is Being Studied For The Treatment Of Retinitis Pigmentosa, Choroideremia, And Stargardt Disease. It Is A Molecular Photoswitch That Has The Potential To Restore Vision In Patients With Inherited And/Or Age-Related Retinal Degeneration. Kio-104 Is Being Developed For The Treatment Of Posterior Non-Infectious Uveitis. It Is A Next-Generation, Non-Steroidal, Immuno-Modulatory, And Small-Molecule Inhibitor Of Dihydroorotate Dehydrogenase.